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Abstract
We aimed to compare risk of death, relapse, neutropenia and infection requiring hospital admission between unselected ANCA-
associated vasculitis (AAV) patients according to whether cyclophosphamide induction was by daily oral (PO) or pulse intrave-
nous (IV) route. We identified all newly diagnosed AAV patients treated with PO or IV cyclophosphamide between March 2007
and June 2013. We used Cox and logistic regression models to compare mortality, relapse and adverse events and adjusted these
for age, renal function and other significant confounders. Fifty-seven patients received PO and 57 received IV cyclophospha-
mide. One-year survival was 86.0% in PO and 98.2% in IV patients; all-time adjusted hazard ratio (HR) for PO compared to that
of IV cyclophosphamide was 1.8 (95% CI 0.3–10.6, P = 0.54). One-year relapse-free survival was 80.7% in PO compared to
87.3% in IV patients, all-time adjusted HR 3.8 (0.2–846, P = 0.37). During the first 12 months, neutropenia of ≤ 0.5 × 109/L
occurred in 9 (16%) PO and 0 (0%) IV cyclophosphamide patients (P = 0.003). The number of patients admitted with one ormore
infections was 16 (28%) in the PO group and 9 (16%) in the IV group, adjusted OR 2.2 (0.6–8.6, P = 0.23). We observed an
increased risk of neutropenia, a trend towards increased risk of death and an admission with infection with PO cyclophospha-
mide. This adds certainty to previous studies, indicating that PO administration induces greater marrow toxicity. Infection-related
admissions within 12 months of starting cyclophosphamide were higher than those in clinical trials, possibly reflecting the
unselected nature of this cohort.
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Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is the commonest life-threatening vasculitis
of adults [1], and is characterised by inflammation of small
and medium blood vessels, and associated with detectable
ANCAs in serum. It comprises three overlapping conditions:
granulomatosis with polyangiitis (formerly known as
Wegener’s granulomatosis), microscopic polyangiitis and eo-
sinophilic granulomatosis with polyangiitis (formerly known
as Churg-Strauss syndrome). National and international
guidelines recommend initial remission induction treatment
with cyclophosphamide [2, 3].
Cyclophosphamide is given either by daily oral (PO) or
pulsed intravenous (IV) administration. The pulsed IV route
is considered to have less toxicity; and CYCLOPS, an inter-
national, multi-centre clinical trial (n = 149) comparing the
two regimens, demonstrated that both treatment routes were
equally efficacious. Pulsed IV therapy had fewer side effects
including leukopenia but is reported to have a higher relapse
rate than the continuous oral route; however, long-term fol-
low-up showed no difference in mortality or renal function at
5 years with either route [4, 5].
In many centres in the UK, people with AAV who present
to rheumatology receive IV therapy and those who present to
nephrology receive PO therapy [6]. There has been no
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comparison of the outcomes in routine clinical practice ac-
cording to treatment route. This is relevant because patients
with AAV in randomised trials are unlikely to be representa-
tive of all patients with AAV [7]. It is important to evaluate
any effect of this variation in treatment route, not least because
delivering day-case IV therapy has significantly higher
healthcare costs.
Observational studies are an increasingly important ap-
proach for studying health outcomes in rare diseases [8]. In
Nottingham, we previously identified a complete incidence
cohort of AAV patients (March 2007–June 2013), with the
treating specialty (rheumatology or nephrology) usually deter-
mined by the presence or absence of significant renal involve-
ment. We aimed to compare outcomes of death, relapse, neu-
tropenia, and infection requiring hospital admission between
the two treatment groups in this unselected cohort which rep-
resents real-life clinical practice.
Methods
All patients diagnosed with AAV at Nottingham University
Hospitals NHS Trust between March 2007 and June 2013
have previously been identified by multiple case ascertain-
ment strategies as part of an institutional audit [9]. In this
study, we included all incident cases diagnosed between
March 2007 and June 2013 and treated with cyclophospha-
mide. Diagnosis of AAVwas classified according to the EMA
criteria [10]. Retrospective case note analysis was undertaken
to ascertain route of administration and baseline characteris-
tics known to be associated with outcomes [11–14] including
age, sex, baseline creatinine and eGFR, haemoglobin and
white cell count, documented organ system involvement,
ANCA status (anti-PR3, anti-MPO, negative), diagnosis, re-
nal involvement and plasma exchange. Patients were followed
up from time of diagnosis to their death ormost recent hospital
assessment. Outcomes were as follows: time to death, time to
end stage renal failure, time to first relapse and hospital ad-
missions due to infection or neutropenic sepsis in the first year
after diagnosis. Occurrence of end stage renal failure (ESRF),
diabetes, venous thromboembolism (VTE), cardiovascular
event (myocardial infarction (MI) or stroke) and cancer during
follow-up was also collected. Age was categorised into four
groups: (i) < 50, (ii) 50 < 60, (iii) 60 < 70, (iv) ≥ 70 years and
eGFR into bands of (i) > 60 ml/min/1.73m2, (ii) 30–60, (iii) <
30 but not on dialysis, (iv) requiring dialysis within 1month of
diagnosis.
Differences in mortality and time to relapse were assessed
using Kaplan-Meier methods and Cox regression. Differences
between treatment routes in neutropenia and infections requir-
ing admission within the first year after diagnosis were
analysed by Fisher’s exact test and logistic regression.
Regression models are reported as crude (unadjusted)
estimates and estimates adjusted for age category, sex, eGFR
category and ANCA type which were included as a priori
confounders. Data were analysed using the Stata 14 statistical
software (StataCorp LP, College Station, TX, USA).
Ethics
This study was approved by the Nottingham University
Hospitals NHS Trust clinical audit department, as a service
evaluation component of an audit (project number 13-037C).
Informed patient consent was not required for this study.
Reporting guidelines
This study has been reported following the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [15].
Results
One hundred fourteen patients started cyclophosphamide for a
new diagnosis of AAV during the study period and were in-
cluded in the analysis: 57 patients received PO cyclophospha-
mide and 57 patients received IV cyclophosphamide. Equal
numbers occurred in each group by chance. Overall mean
follow-up was 4.8 years: 4.4 (standard deviation [SD] 2.8)
years in the PO and 5.3 (SD 2.6) years in the IV group.
Baseline characteristics
Baseline characteristics and clinical features were significant-
ly different between the two groups (Table 1), reflecting the
clinical differences influencing whether patients would pres-
ent to nephrology or rheumatology. The patients who received
PO cyclophosphamide were older, had more renal involve-
ment with higher creatinine and were more likely to have
MPO-ANCA.
Treatment
Prednisolone dose at diagnosis was median 45 mg (IQR 30–
60mg) in the PO cyclophosphamide group and 60mg (42.5—
60 mg) in the IV cyclophosphamide group. By 1 year, both
groups had median prednisolone dose of 5 mg (Table 1) in
patients who had not relapsed. Three patients had
cyclophosphamide-refractory disease at 3 months: one in the
PO cyclophosphamide group and two in the IV cyclophospha-
mide group. Thirty-two patients received plasma exchange:
24 in the PO cyclophosphamide group and 8 in the IV cyclo-
phosphamide group.
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Outcomes
Results are shown in Table 2.
Mortality/survival
Overall, 22 patients died in 553 patient-years of follow-up (mor-
tality rate of 39.8 per thousand person-years). One-year survival
was 86.0% in PO and 98.2% in IV patients. Survival to the end
of the follow-up period was 70% in PO and 91% in IV patients.
Unadjusted hazard ratio (HR) for the whole follow-up period for
PO compared to IV cyclophosphamide was 3.9 (95% CI 1.4–
10.4), and adjusted HR was 1.9 (95% CI 0.3–12.0, P = 0.47).
Relapse
One-year relapse rate was 4 (7%) in PO and 6 (11%) in IV
patients; relapse rate to the end of the follow-up period was 14
(25%) in PO and 24 (42%) in IV patients. Unadjusted hazard
ratio (HR) for the whole follow-up period for PO compared to
that of IV cyclophosphamide was 0.5 (95% CI 0.3–1.0), and
adjusted HR was 1.0 (95% CI 0.4–2.6, P = 1.00).
Neutropenia
During the first 12 months after initiating treatment, docu-
mented neutropenia of ≤ 0.5 × 109/L occurred in 9 (16%) PO
and 0 (0%) IV patients (P = 0.003). It was not possible to
calculate an odds ratio because the outcome did not occur in
IV patients. The lowest documented neutrophil count was 0.1
in the PO group and 0.94 in the IV group. Five patients in the
PO group were treated for neutropenic sepsis with no recorded
cases in the IV group.
Infection
Overall, 25 (22%) patients were admitted to hospital with ≥ 1
infection during 12months after initiation treatment: 16 (28%)
Table 1 Characteristics and








P value for difference between
groups
Age (median, IQR) 72 (65–78) 55 (44–68) < 0.0001*
Male 28 (49%) 31 (54%) 0.57
PR3-ANCA 22 (39%) 35 (61%) 0.02*
MPO-ANCA 32 (56%) 17 (30%)
ANCA negative 3 (5%) 5 (9%)
Renal involvement 56 (98%) 26 (46%) < 0.001*
ENT involvement 9 (16%) 33 (58%) < 0.001*
Neurological
involvement
2 (4%) 19 (33%) < 0.001*
Eye involvement 0 5 (9%) 0.02*
Abdominal involvement 0 6 (11%) 0.01*
General/systemic
involvement
18 (32%) 27 (47%) 0.09
Cutaneous involvement 5 (9%) 9 (16%) 0.25
Pulmonary involvement 23 (40%) 25 (46%) 0.57
Cardiovascular
involvement
2 (4%) 2 (4%) 1.0
Serum creatinine 295 (158–618) 80 (68–100) < 0.0001*
Plasma exchange 24 (42%) 8 (14%) 0.001*
Refractory disease 1 (2%) 2 (4%) 0.5
Follow-up time (years) 4.0 (2.6–6.7) 5.1 (3.2–7.6) 0.10
Prednisolone dose at
diagnosis
45 (30–60) 60 (42.5–60) 0.06
Prednisolone dose at
3 months
15 (15–20) 15 (10–20) 0.15
Prednisolone dose at
6 months
10 (7.5–10) 7.5 (5–10) 0.10
Prednisolone dose at
1 year
5 (5–7.5) 5 (2.5–7.5) 0.15
Creatinine at 5 years 142 (76–206) 86 (76–107) < 0.0001*
*P value significant at 95% confidence level
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with PO and 9 (16%) with IV cyclophosphamide. Unadjusted
OR for admission with infection in PO compared to that of IV
cyclophosphamide was 2.0 (95% CI 0.8–5.0), and adjusted
OR was 2.2 (95% CI 0.6–8.7, P = 0.24).
Other outcomes
Overall, ESRF occurred in 20 (18%); incident diabetes, in 14
(13%); VTE, in 8 (7%); MI, in 8 (7%); stroke, in 8 (7%) and
any cancer, in 9 (8%).
Cause of death
Cause of death is recorded for 18 of the 22 deaths. Of the 9
deaths in the first year, 5 (56%) were due to infection (4 pneu-
monia, 1 E. coli sepsis), 1 progressive lung fibrosis, 1 lung
cancer, 1 retroperitoneal haemorrhage and 1 unknown. Of the
13 deaths after the first year, 7 (54%) were due to infection (3
pneumonia, 2 infective exacerbation of bronchiectasis, 2 sys-
temic sepsis with source not specified) 1 MI, 1 old age, 1 renal
failure and 3 unknown.
Discussion
Patients who received PO and IV cyclophosphamide were
significantly different at baseline, reflecting differences in
the AAV phenotype between patients presenting to rheuma-
tology and nephrology departments. Patients presenting to
nephrology were older and had almost universal renal in-
volvement, both of which are associated with worse out-
comes. Although there were stark differences in crude out-
comes, once adjusted for age, sex and renal function, there
were no significant differences between PO and IV cyclophos-
phamide in survival or relapse rates. PO cyclophosphamide
was associatedwith a significant risk of neutropenia compared
to IV cyclophosphamide. Although not significant, there was
a trend towards an increased risk of admission with infection
in the PO group.
The main strengths of our study are long follow-up times
(mean 4.8 years) and that data capture-recapture techniques
suggested our case identification technique resulted in near
complete case capture [9], resulting in an unselected cohort
likely to be representative of real-life outcomes in routine
clinical practice. This suggests our results may be more gen-
eralizable to the whole population of AAV patients than those
of clinical trials, whose participants represent selected patients
and have been shown to differ from patients within observa-
tional cohorts of AAV [7].
Our study is limited by its observational nature. However,
observational studies of outcome are important in rare dis-
eases and can help to increase the level of certainty about
specific clinical questions. The main limitation is the risk of
confounding; treatment route was likely to have been deter-
mined by the baseline characteristics, with older patients and
those with renal dysfunction (both risk factors for poor out-
comes) more likely to be treated by nephrology and therefore
receive PO cyclophosphamide. The sample size was too small
to use propensity score methods to adjust for this; we therefore
adjusted the analysis for the known confounders (age catego-
ry, sex, eGFR category and ANCA type). We are unlikely to
have been completely successful in adjusting; however, de-
spite the theoretical limitations, our adjustment led to attenu-
ation of the crude differences in treatment effects in the ad-
justed models.
Whereas in the CYCLOPS study, patients received a me-
dian cyclophosphamide dose of 8.58 g IVand 18.05 g PO [4]
and our protocol aims to deliver similar cyclophosphamide
doses of ~ 10 g to both PO (2 mg/kg for 3 months) and IV
(15 mg/kg for 10 cycles over 6 months) groups. However, our
remission maintenance protocol mimics the CYCLOPS pro-
tocol using azathioprine as the first-line maintenance agent. In
light of this, but keeping in mind that we are comparing a
randomised controlled trial where baseline differences be-
tween the treatment groups are evened out by randomisation





Unadjusted HR/OR for PO
cyclophosphamide




Mortality 17 (30%) 5 (9%) 3.9 (1.4–10.4) 1.9 (0.3–12.0) P = 0.47
Relapse 14 (25%) 24 (42%) 0.5 (0.3–1.0) 1.0 (0.4–2.6) P = 1.00
Neutropenia 9 (16%) 0 (0%) – – P = 0.003*
Infection requiring
admission
16 (28%) 9 (16%) 2.0 (0.8–5.0) 2.2 (0.6–8.7) P = 0.24
Hazard ratio (HR) for mortality and relapse rates during the whole follow-up period was calculated using Cox regression. Odds ratio (OR) for
neutropenia or infection requiring hospital admission within 1 year after diagnosis was calculated using logistic regression
*P value from Fisher’s exact test (unadjusted for confounders)
a Adjusted for age category, sex, eGFR category and ANCA type
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to our cohort where there are very different baseline charac-
teristics in the treatment groups, it is interesting to compare
our results to the CYCLOPS trial. We observed a similar non-
significant higher mortality in the PO arm but not a greater risk
of relapse in the IVarm [4, 5]. It is tempting to speculate that
this may be linked to differing cyclophosphamide doses used
in the two scenarios. As in CYCLOPS, we saw no statistically
significant difference in survival or renal function at the end of
the study period.
Contrasting with CYCLOPS, we observed an overall rate
of admission with infection during the first year of 22% (28%
PO, 16% IV). Only a few admissions were at times of frank
neutropenia, and the steroid doses in our cohort were margin-
ally lower than those of the CYCLOPS protocol. The average
age of patients in our IV treatment cohort was similar to that of
the CYCLOPS cohort; however, our PO cohort was signifi-
cantly older; advancing age is a risk factor for hospitalisation
with infection. Additionally, a quarter of our cohort was made
up of patients who would have been excluded by the
CYCLOPS trial protocol, e.g. life-threatening disease or cre-
atinine > 500 μmol/L.
The finding of differences between patients with AAV pre-
senting to nephrology or rheumatology services is consistent
with that of a recent paper from Ireland describing patients
with AAV presenting to Galway University Hospitals from
June 2002 to July 2011 [16]. They reported on 45 patients,
and like our study found that the patients presenting to ne-
phrology were significantly older and had higher creatinine
than those presenting to rheumatology. Additionally, they re-
ported baseline Birmingham Vasculitis Activity Scores
(BVAS) and found these to be significantly higher among
patients presenting to nephrology compared to rheumatology.
The main cause of mortality in our study was infection,
accounting for 56% of deaths in the first year after diagnosis
and 54% of later deaths, with none recorded as due to active
vasculitis, suggesting that in our cohort, the increased risk of
infection extends beyond the first year. This does not
completely align with previous studies of cause of death
where in the first year after diagnosis, the most frequent causes
were infection (32–48% of deaths) then active vasculitis (18–
19% of deaths), with later deaths most frequently due to car-
diovascular disease, malignancy and renal failure [14, 17].
In conclusion, PO cyclophosphamide was associated with
an increased risk of neutropenia, and a trend towards increased
risk of death, and admission with infection with PO cyclo-
phosphamide. This adds to the level of certainty that PO cy-
clophosphamide is associated with greater marrow toxicity
that was suggested in the CYCLOPS study results and a pre-
vious meta-analysis that demonstrated increased risk of leu-
kopenia with this route [18]. This is important, because leu-
kopenia is known to be associated with increased mortality
and infection, even though this was not statistically demon-
strated in the cohort reported here [19, 20].
Of note in our study, in the setting of routine clinic practice,
over 20% of the patients were admitted with infection in the
first year. It remains to be seen if further developments in the
management of ANCA vasculitis (e.g. steroid sparing proto-
cols) can impact upon this, but it highlights the need for on-
going clinical vigilance during the treatment of this complex
disease.
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